A New Way Forward
for Autoimmune Disease
Our Mission
We Are Nkarta
The current treatment paradigm for autoimmune disease is not good enough — a reality many of our colleagues understand firsthand as patients or caregivers themselves. This perspective shapes our sense of urgency to transform the standard of care and improve the lives of patients living with rheumatic disease.
Patients First
Our Clinical Trial Promise
Instead of asking people with serious diseases to reconstruct their lives around our studies, drug developers should be striving to design our research around their lives. Read about what we’re doing to make clinical trial opportunities more accessible and equitable.
Nature
Boosted Killer Cells Show Promise For Autoimmune Disease
“Supercharged ‘natural killer’ cells could become a potent way to reset a disordered immune system,” according to one of the world's most prestigious scientific journals.
Our Autoimmune Targets
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of autoimmune diseases. Our proprietary technology is designed to harness the inherent disease-fighting capabilities of these immune cells to act against cells that are dysfunctional, diseased or otherwise abnormal.
Follow us on Linkedin
Today, we shared initial clinical data at #ACR2026 from our Ntrust program evaluating NKX019, our investigational CAR NK cell therapy candidate, in our lead indications, myositis and systemic sclerosis. At Nkarta, it is our mission to deliver a next-generation cell therapy designed to be well tolerated and accessible for patients. We believe these initial data highlight our potential to fulfill this mission.
Dr. Guillermo Valenzuela, principal investigator, is presenting initial clinical data from the Ntrust program to his rheumatology colleagues at ACR this week. “I’ve been participating in the Ntrust clinical trials in my community clinic, IRIS, in Plantation, Florida, where we’re treating patients on an outpatient basis followed by a two-hour, post-infusion observation period and subsequent discharge home,” he said. “Being able to offer this investigational therapy right here in our community clinic means our patients can receive treatment close to home, with the care team they already know.”
